PinkDx (Series A)

Founding Year: 2024
Traction: PinkDx will initially focus on improving the diagnostic outcomes for women who have vague symptoms that may signal a gynecological cancer. Each year in the United States, an estimated 1.5 million women present with general symptoms including bloating, pelvic pain, and abnormal bleeding, for which the cause is not clear. Over 100,000 women in the U.S. are ultimately diagnosed with a gynecological cancer each year.
Organizations Involved: Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital, Mayo Clinic
Founders: Bonnie Anderson, Giulia C. Kennedy, Tim McMeekan, Alison Cowan, Isaac Ro
Company Description: PinkDx is an early-stage company focused on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and providing answers that have an immediate, positive impact on their lives. The company's first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. PinkDx is privately held, with Series A funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital, and Mayo Clinic.
Market: Women's Health
Location: Daly City, CA, US
Coinvestors: Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital, Mayo Clinic